Literature DB >> 8977493

Choroidal concentration of interferon after retrobulbar injection.

H Lincoff1, P Stanga, A Movshovich, A Palleroni, B Madjarov, R Rivera, R Silverman.   

Abstract

PURPOSE: To determine whether recombinant human interferon alpha-2a (IFN alpha-2a) would diffuse into the choroid in significant amounts from a retrobulbar depot.
METHODS: One million international units of IFN alpha-2a were injected into the retrobulbar space of the eyes of 17 rabbits, and choroidal and serum concentrations were measured at 1, 2, 4, 8, 12, and 24 hours. The same dose of IFN alpha-2a was injected subcutaneously into 10 rabbits, and choroidal and serum concentrations were measured at the same intervals for comparison. Parabulbar and ocular tissues were studied by light microscopy for evidence of local toxicity.
RESULTS: Peak concentration IFN alpha-2a in the choroid after retrobulbar injection occurred at 2 hours and averaged 32,000 IU/mg. Peak concentration in the serum occurred at 4 hours and averaged 227 IU/ml. Concentrations in choroid and serum fell rapidly, and IFN alpha-2a was not detectible at 24 hours. No IFN alpha-2a was detected in the choroid of the paired eye, and only a trace (< 50 IU/mg) was found in either eye after subcutaneous injection. Light microscopy revealed some lymphocytes in the fat adjacent to the retrobulbar depot after six daily injections of IFN alpha-2a or saline. Sclera, choroid, and retina appeared unaffected.
CONCLUSIONS: IFN alpha-2a diffuses into the choroid from a retrobulbar depot in significant amounts. The serum concentration from a retrobulbar injection is < 1% of the choroidal concentration. The retrobulbar route to the choroid may be optimal for testing the effect of IFN alpha-2a on choroidal neovascularization.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8977493

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  6 in total

1.  Enhancement of scleral macromolecular permeability with prostaglandins.

Authors:  R N Weinreb
Journal:  Trans Am Ophthalmol Soc       Date:  2001

2.  Topical Interferon Alpha 2b in the Treatment of Refractory Diabetic Macular Edema.

Authors:  Arash Maleki; Andrew Phillips Stephenson; Fedra Hajizadeh
Journal:  J Ophthalmic Vis Res       Date:  2020-10-25

3.  Inhibition of experimental autoimmune uveoretinitis by systemic and subconjunctival adenovirus-mediated transfer of the viral IL-10 gene.

Authors:  Y De Kozak; B Thillaye-Goldenberg; M-C Naud; A Vianna Da Costa; C Auriault; C Verwaerde
Journal:  Clin Exp Immunol       Date:  2002-11       Impact factor: 4.330

4.  Improvement of pseudophakic cystoid macular edema with subconjunctival injections of interferon α2b:a case report.

Authors:  Hossein Aghaei; Acieh Es'haghi; Rama Pourmatin
Journal:  Am J Ophthalmol Case Rep       Date:  2022-03-23

5.  Topical interferon alpha 2b in the treatment of refractory pseudophakic cystoid macular edema.

Authors:  Arash Maleki; Hossein Aghaei; Stacey Lee
Journal:  Am J Ophthalmol Case Rep       Date:  2018-03-07

6.  Subtenon injection of natural leukocyte interferon α-2a in diabetic macular edema: a case report.

Authors:  Mauro Cellini; Nicole Balducci; Ernesto Strobbe; Emilio C Campos
Journal:  BMC Ophthalmol       Date:  2013-10-28       Impact factor: 2.209

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.